Contrasting Tarsus Pharmaceuticals (NASDAQ:TARS) and Pluri (NASDAQ:PLUR)
Pluri (NASDAQ:PLUR – Get Free Report) and Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Insider & Institutional Ownership 16.6% of Pluri shares […]
More Stories
Booking (NASDAQ:BKNG) Rating Increased to Buy at StockNews.com
StockNews.com upgraded shares of Booking (NASDAQ:BKNG – Free Report) from a hold rating to a buy rating in a research...
Expedia Group (NASDAQ:EXPE) Lowered to “Buy” Rating by StockNews.com
StockNews.com cut shares of Expedia Group (NASDAQ:EXPE – Free Report) from a strong-buy rating to a buy rating in a...
StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)
StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report published on Saturday morning. The brokerage...
United Microelectronics (NYSE:UMC) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of United Microelectronics (NYSE:UMC – Free Report) from a hold rating to a buy rating in a...
SenesTech (NASDAQ:SNES) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of SenesTech (NASDAQ:SNES – Free Report) in a report released on Saturday. The firm issued...
QuickLogic (NASDAQ:QUIK) Posts Earnings Results, Misses Expectations By $0.01 EPS
QuickLogic (NASDAQ:QUIK – Get Free Report) issued its quarterly earnings data on Monday. The semiconductor company reported ($0.06) earnings per...